Oxford Global’s 10th Annual Biomarkers congress is Europe’s leading congress in the field. Join us to hear from prominent decision makers discussing the latest challenges in Biomarker research. Participate in formal 1-1 meetings and an informal networking drinks reception with over 250 senior level attendees to idea-share amongst the most influential biomarker industry members.
The rising demand for personalised medicine and companion diagnostics has increased the opportunity for biomarkers research within the pharmaceutical industry. The global biomarkers market is expected to reach over $40 billion by 2018; much credit being given to advances in discovery technologies. Novel omics technologies such as genome sequencing has allowed for new research opportunities within the biomarker field.
The conference programme will consist of 6 interactive streams covering:
• Biomarkers in Discovery and Development
• Companion Diagnostics
• Biomarker Discovery, Verification & Validation
• Innovations In Biomarker Research
• Biomarkers in Clinical Development & Diagnostics
• Clinical Trials & Personalised Medicine
On day one the Biomarkers Congress will cover solutions to the most pressing discovery and development challenges, opportunities of emerging companion diagnostic technologies and the importance of drug-diagnostics co-development. Key solution providers and industry experts have recently joined forces in order to access highly sophisticated technologies and divide costs.
On day two hear about the latest partnership and collaboration strategies from the top market players in the biomarker industry. Our expert panel will also share case studies on biomarker discovery, verification and validation including genomic, proteomic and metabolomics markers.
To build on the success of last year’s event, we are please to announce that the Biomarkers Congress will be co-located with the 2nd Annual Biomarkers in Clinical Development Congress, focussing on the role of biomarkers in clinical decision making, clinical diagnostics and clinical trial design. Industry leaders will discuss the importance of translating scientific innovations into patient benefits.